NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 PLTR
Palantir
-- 79.890 CRNC
Cerence
-- 19.330 MSTR
MicroStrategy
-- 339.660 
NEWS
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic Biosciences (NASDAQ:XBIO) has entered into a Materials Transfer Agreement with Tokyo Medical University to advance its systemic DNase program. The agreement involves evaluating the effects of human recombinant DNase I (rhDNase I) in combination with chemotherapy for Ewing sarcoma, an aggressive pediatric cancer.
Professor Takuro Nakamura will lead the research using a proprietary immunocompetent preclinical mouse model. This model reflects the characteristics of human Ewing sarcoma and has shown translational relevance. The study aims to assess DNase's ability to reduce neutrophil extracellular traps(NETs) in the tumor microenvironment and enhance chemotherapy efficacy.
Previous clinical studies at Tel Aviv Medical Center demonstrated that NETs formation in Ewing sarcoma tumors is an independent prognostic factor, with higher NETs levels associated with poor prognosis and treatment response.
Professor Takuro Nakamura will lead the research using a proprietary immunocompetent preclinical mouse model. This model reflects the characteristics of human Ewing sarcoma and has shown translational relevance. The study aims to assess DNase's ability to reduce neutrophil extracellular traps(NETs) in the tumor microenvironment and enhance chemotherapy efficacy.
Previous clinical studies at Tel Aviv Medical Center demonstrated that NETs formation in Ewing sarcoma tumors is an independent prognostic factor, with higher NETs levels associated with poor prognosis and treatment response.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment